Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges

Reuters

05-28

Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges

On May 28, 2025, Boston Scientific Corporation announced its decision to discontinue worldwide sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems. The company will also no longer pursue U.S. FDA approval or seek approval in other regions. This decision follows recent discussions with regulators that have led to increased clinical and regulatory requirements. The company determined that the resources and investments necessary to meet these new requirements are prohibitive. Despite the anticipated financial impact of discontinuing ACURATE, Boston Scientific still expects to meet its second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company has not reaffirmed its GAAP EPS guidance for the same period and plans to provide more information in its second quarter 2025 earnings call.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-25-000033), on May 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2538473935"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538473935\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2538473935?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-28 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538473935","market":"us","top_or_hot":-1,"title":"Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On May 28, 2025, Boston Scientific Corporation announced its decision to discontinue worldwide sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems. The company will also no longer pursue U.S. FDA approval or seek approval in other regions. This decision follows recent discussions with regulators that have led to increased clinical and regulatory requirements. The company determined that the resources and investments necessary to meet these new requirements are prohibitive. Despite the anticipated financial impact of discontinuing ACURATE, Boston Scientific still expects to meet its second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company has not reaffirmed its GAAP EPS guidance for the same period and plans to provide more information in its second quarter 2025 earnings call.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-25-000033), on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-28 19:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On May 28, 2025, Boston Scientific Corporation announced its decision to discontinue worldwide sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems. The company will also no longer pursue U.S. FDA approval or seek approval in other regions. This decision follows recent discussions with regulators that have led to increased clinical and regulatory requirements. The company determined that the resources and investments necessary to meet these new requirements are prohibitive. Despite the anticipated financial impact of discontinuing ACURATE, Boston Scientific still expects to meet its second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company has not reaffirmed its GAAP EPS guidance for the same period and plans to provide more information in its second quarter 2025 earnings call.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-25-000033), on May 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL7kBbTN:1","article_id":"2538473935","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538473935","pubTimestamp":1748432790,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"On May 28, 2025, Boston Scientific Corporation announced its decision to discontinue worldwide sales of its ACURATE neo2 and ACURATE Prime Aortic Valve Systems. The company will also no longer pursue U.S. FDA approval or seek approval in other regions. This decision follows recent discussions with regulators that have led to increased clinical and regulatory requirements. The company determined that the resources and investments necessary to meet these new requirements are prohibitive. Despite the anticipated financial impact of discontinuing ACURATE, Boston Scientific still expects to meet its second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company has not reaffirmed its GAAP EPS guidance for the same period and plans to provide more information in its second quarter 2025 earnings call.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"波士顿科学公司因监管挑战而停产ACURATE阀门系统","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":0.9},"content_text":"Boston Scientific Corporation Discontinues ACURATE Valve Systems Amid Regulatory Challenges\n    \n\n        On May 28, 2025, Boston Scientific Corporation announced its decision to discontinue worldwide sales of its ACURATE neo2™ and ACURATE Prime™ Aortic Valve Systems. The company will also no longer pursue U.S. FDA approval or seek approval in other regions. This decision follows recent discussions with regulators that have led to increased clinical and regulatory requirements. The company determined that the resources and investments necessary to meet these new requirements are prohibitive. Despite the anticipated financial impact of discontinuing ACURATE, Boston Scientific still expects to meet its second quarter and full year 2025 sales and adjusted earnings per share guidance. However, the company has not reaffirmed its GAAP EPS guidance for the same period and plans to provide more information in its second quarter 2025 earnings call.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Boston Scientific Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000885725-25-000033), on May 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}